Janus Henderson Group PLC Sells 240,346 Shares of Dyne Therapeutics, Inc. $DYN

Janus Henderson Group PLC lessened its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 1.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,647,376 shares of the company’s stock after selling 240,346 shares during the quarter. Janus Henderson Group PLC owned about 0.08% of Dyne Therapeutics worth $247,427,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. raised its holdings in Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Orbis Allan Gray Ltd bought a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $93,926,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Dyne Therapeutics in the 2nd quarter valued at about $30,378,000. Perceptive Advisors LLC grew its position in shares of Dyne Therapeutics by 543.7% during the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after buying an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Dyne Therapeutics by 572.9% during the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after buying an additional 2,565,570 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $25.73 on Friday. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $4.80 billion, a P/E ratio of -7.73 and a beta of 1.06. The business has a 50-day moving average of $21.08 and a 200-day moving average of $18.82. Dyne Therapeutics, Inc. has a 1 year low of $9.57 and a 1 year high of $26.26.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.34). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Sanford C. Bernstein increased their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. TD Cowen began coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating for the company. Royal Bank Of Canada upped their target price on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.58.

Insider Buying and Selling at Dyne Therapeutics

In other news, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the transaction, the chief financial officer owned 121,563 shares of the company’s stock, valued at $2,476,238.31. The trade was a 1.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jason P. Rhodes sold 297,211 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director directly owned 2,962 shares of the company’s stock, valued at $68,896.12. This trade represents a 99.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders bought 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. Insiders own 9.46% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.